302 related articles for article (PubMed ID: 21455214)
1. Intracellular reactive oxygen species are essential for PI3K/Akt/mTOR-dependent IL-7-mediated viability of T-cell acute lymphoblastic leukemia cells.
Silva A; Gírio A; Cebola I; Santos CI; Antunes F; Barata JT
Leukemia; 2011 Jun; 25(6):960-7. PubMed ID: 21455214
[TBL] [Abstract][Full Text] [Related]
2. IL-22 induced cell proliferation is regulated by PI3K/Akt/mTOR signaling cascade.
Mitra A; Raychaudhuri SK; Raychaudhuri SP
Cytokine; 2012 Oct; 60(1):38-42. PubMed ID: 22840496
[TBL] [Abstract][Full Text] [Related]
3. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.
Fuka G; Kantner HP; Grausenburger R; Inthal A; Bauer E; Krapf G; Kaindl U; Kauer M; Dworzak MN; Stoiber D; Haas OA; Panzer-Grümayer R
Leukemia; 2012 May; 26(5):927-33. PubMed ID: 22094587
[TBL] [Abstract][Full Text] [Related]
4. PI3K/mTOR inhibition upregulates NOTCH-MYC signalling leading to an impaired cytotoxic response.
Shepherd C; Banerjee L; Cheung CW; Mansour MR; Jenkinson S; Gale RE; Khwaja A
Leukemia; 2013 Mar; 27(3):650-60. PubMed ID: 23038273
[TBL] [Abstract][Full Text] [Related]
5. Activation of PI3K is indispensable for interleukin 7-mediated viability, proliferation, glucose use, and growth of T cell acute lymphoblastic leukemia cells.
Barata JT; Silva A; Brandao JG; Nadler LM; Cardoso AA; Boussiotis VA
J Exp Med; 2004 Sep; 200(5):659-69. PubMed ID: 15353558
[TBL] [Abstract][Full Text] [Related]
6. Involvement of PI3K-AKT-mTOR pathway in protein kinase CKII inhibition-mediated senescence in human colon cancer cells.
Park JH; Kim JJ; Bae YS
Biochem Biophys Res Commun; 2013 Apr; 433(4):420-5. PubMed ID: 23523798
[TBL] [Abstract][Full Text] [Related]
7. PI3K/AKT/mTORC1 and MEK/ERK signaling in T-cell acute lymphoblastic leukemia: new options for targeted therapy.
Martelli AM; Tabellini G; Ricci F; Evangelisti C; Chiarini F; Bortul R; McCubrey JA; Manzoli FA
Adv Biol Regul; 2012 Jan; 52(1):214-27. PubMed ID: 21983557
[No Abstract] [Full Text] [Related]
8. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
9. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells.
Sekulić A; Hudson CC; Homme JL; Yin P; Otterness DM; Karnitz LM; Abraham RT
Cancer Res; 2000 Jul; 60(13):3504-13. PubMed ID: 10910062
[TBL] [Abstract][Full Text] [Related]
10. The PI3K/Akt/mTOR signaling pathway mediates insulin-like growth factor 1-induced E-cadherin down-regulation and cell proliferation in ovarian cancer cells.
Lau MT; Leung PC
Cancer Lett; 2012 Dec; 326(2):191-8. PubMed ID: 22922215
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway.
Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA
Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907
[TBL] [Abstract][Full Text] [Related]
12. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
13. Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation.
Calviño E; Estañ MC; Simón GP; Sancho P; Boyano-Adánez Mdel C; de Blas E; Bréard J; Aller P
Biochem Pharmacol; 2011 Dec; 82(11):1619-29. PubMed ID: 21889928
[TBL] [Abstract][Full Text] [Related]
14. Copper ions strongly activate the phosphoinositide-3-kinase/Akt pathway independent of the generation of reactive oxygen species.
Ostrakhovitch EA; Lordnejad MR; Schliess F; Sies H; Klotz LO
Arch Biochem Biophys; 2002 Jan; 397(2):232-9. PubMed ID: 11795876
[TBL] [Abstract][Full Text] [Related]
15. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
16. TOR kinase and Ran are downstream from PI3K/Akt in H2O2-induced mitosis.
Radisavljevic ZM; González-Flecha B
J Cell Biochem; 2004 Apr; 91(6):1293-300. PubMed ID: 15048882
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effect of brain-derived neurotrophic factor mediated by autophagy through the PI3K/Akt/mTOR pathway.
Chen A; Xiong LJ; Tong Y; Mao M
Mol Med Rep; 2013 Oct; 8(4):1011-6. PubMed ID: 23942837
[TBL] [Abstract][Full Text] [Related]
18. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia.
Chiarini F; Grimaldi C; Ricci F; Tazzari PL; Evangelisti C; Ognibene A; Battistelli M; Falcieri E; Melchionda F; Pession A; Pagliaro P; McCubrey JA; Martelli AM
Cancer Res; 2010 Oct; 70(20):8097-107. PubMed ID: 20876803
[TBL] [Abstract][Full Text] [Related]
19. A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling.
Yuan Y; Zhang A; Huang S; Ding G; Chen R
Am J Physiol Renal Physiol; 2011 Feb; 300(2):F393-402. PubMed ID: 21123490
[TBL] [Abstract][Full Text] [Related]
20. T-cadherin attenuates insulin-dependent signalling, eNOS activation, and angiogenesis in vascular endothelial cells.
Philippova M; Joshi MB; Pfaff D; Kyriakakis E; Maslova K; Erne P; Resink TJ
Cardiovasc Res; 2012 Mar; 93(3):498-507. PubMed ID: 22235028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
